Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2016-000642-62 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to evaluate the efficacy and safety of upadacitinib compared to placebo in inducing clinical remission (per Adapted Mayo score) in participants with moderately to severely active ulcerative colitis (UC).
Study M14-675 consists of 2 parts, Part 1 and Part 2. Part 1 is a randomized, double-blind, placebo-controlled 8-week induction period. Part 2 is an open-label, 8-week extended treatment period for participants who did not achieve clinical response at Week 8 in Part 1.
Eligible participants are randomized in a 2:1 ratio to one of the two treatment groups (upadacitinib 45 mg or matching placebo) for 8 weeks. The randomization is stratified by biologic inadequate responder (bio-IR) status (bio-IR vs non-bio-IR), corticosteroid use (yes or no), and Adapted Mayo score (≤ 7 or > 7) at Baseline. Within bio-IR, the randomization is further stratified by number of prior biologic treatments (≤ 1 or > 1). Within non-bio-IR, the randomization is further stratified by previous biologic use (yes or no).
Participants who achieve clinical response defined by Adapted Mayo Score at Week 8 or Week 16 and do not meet any study discontinuation criteria are eligible to enroll into Study M14-234 Substudy 3 (NCT02819635; 52-week maintenance study) or Study M14-533 Cohort 1 (NCT03006068; long-term follow-up study).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Upadacitinib 45 mg | Experimental | Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period. |
|
| Placebo | Placebo Comparator | Participants received placebo matching to upadacitinib once daily for 8 weeks. Participants who did not achieve clinical response per Adapted Mayo score at Week 8 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Tablet for oral administration |
| |
| Upadacitinib |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 | The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as an Adapted Mayo score ≤ 2, with SFS ≤ 1 and not higher than Baseline, RBS of 0, and endoscopic subscore ≤ 1. | Week 8 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Endoscopic Improvement at Week 8 | Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). |
Not provided
Inclusion Criteria:
- Male or female participants ≥ 16 and ≤ 75 years of age at Baseline Note: Adolescent participants at the age of 16 or 17 years old will be eligible to participate if approved by the country or regulatory/health authorities.
Note: Adolescent participants at the age of 16 or 17 years old must weigh ≥ 40 kilograms and meet the definition of Tanner Stage 5 at the Screening Visit.
Note: Participants who have had inadequate response, loss of response to conventional therapy but have not failed biologic therapy (Non-bio-IR) and have received a prior biologic for up to 1 year may be enrolled, however they must have discontinued the biologic for reasons other than inadequate response or intolerance (e.g., change of insurance, well controlled disease), and must meet criteria for inadequate response, loss of response, or intolerance as defined above.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| ABBVIE INC. | AbbVie | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| East View Medical Research, LLC /ID# 216933 | Mobile | Alabama | 36606 | United States | ||
| CB Flock Research Corporation /ID# 206094 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41264726 | Derived | Vermeire S, Colombel JF, Danese S, Panaccione R, Peyrin-Biroulet L, Beck K, Chaparro M, Gisbert JP, Dubcenco E, Klaff J, Naling G, Ford S, Remple V, Joshi N, Suravaram S, Duncan B, Wang Y, Wick-Urban B, Loftus EV. Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease. J Crohns Colitis. 2026 Jan 9;20(1):jjaf198. doi: 10.1093/ecco-jcc/jjaf198. | |
| 40488552 |
| Label | URL |
|---|---|
| This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses. | View source |
Not provided
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
For details on when studies are available for sharing, please refer to the link below.
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.
In Part 1 participants were randomized in a 2:1 ratio to upadacitinib or placebo. Randomization was stratified by biologic-inadequate responder (Bio-IR) status (bio-IR vs non-bio-IR), corticosteroid use (yes or no), and Adapted Mayo score (≤ 7 or > 7) at Baseline. Within bio-IR, randomization was further stratified by number of prior biologic treatments (≤ 1 or > 1). Within non-bio-IR, randomization was further stratified by previous biologic use (yes or no).
This study included a Screening Period of up to 5 weeks, Part 1, and Part 2. Part 1 was a randomized, double-blind, placebo-controlled 8-week induction period. Part 2 was an open-label, 8-week extended treatment period for participants who were clinical non-responders in Part 1.
Participants with moderately to severely active ulcerative colitis (UC) were randomized at 204 sites in 41 countries.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Part 1: Upadacitinib 45 mg | Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. |
| FG001 | Part 1: Placebo | Participants received placebo matching to upadacitinib once daily for 8 weeks. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Part 1: Placebo-controlled Period |
|
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jul 31, 2020 | Oct 29, 2021 |
Not provided
Not provided
Not provided
Not provided
| Drug |
Tablet for oral administration |
|
|
| Week 8 |
| Percentage of Participants With Endoscopic Remission at Week 8 | Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). | Week 8 |
| Percentage of Participants Who Achieved Clinical Response Per Adapted Mayo Score at Week 8 | The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response per the Adapted Mayo Score is defined as a decrease in Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1. | Week 8 |
| Percentage of Participants Who Achieved Clinical Response Per Partial Adapted Mayo Score at Week 2 | The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores:
The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Adapted Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1. | Week 2 |
| Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8 | Histologic endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. | Week 8 |
| Percentage of Participants Who Reported No Bowel Urgency at Week 8 | Bowel urgency was assessed by participants in a subject diary completed once a day. | Week 8 |
| Percentage of Participants Who Reported No Abdominal Pain at Week 8 | Abdominal pain was assessed by participants in a subject diary completed once a day. | Week 8 |
| Percentage of Participants Who Achieved Histologic Improvement at Week 8 | Histologic improvement is defined as a decrease from Baseline in Geboes score. The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. | Week 8 |
| Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8 | The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement. | Baseline (Week 0) to Week 8 |
| Percentage of Participants Who Achieved Mucosal Healing at Week 8 | Mucosal healing is defined as an endoscopic score of 0 and Geboes score < 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. | Week 8 |
| Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8 | The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement. | Baseline (Week 0) to Week 8 |
| Mobile |
| Alabama |
| 36608 |
| United States |
| Arizona Arthritis & Rheumatology Research, PLLC /ID# 211030 | Sun City | Arizona | 85306 | United States |
| Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211887 | Tempe | Arizona | 85284-2604 | United States |
| University of Arizona /ID# 208856 | Tucson | Arizona | 85724 | United States |
| Citrus Valley Gastroenterology /ID# 205627 | Covina | California | 91722-3797 | United States |
| Care Access Research /ID# 217003 | Huntington Beach | California | 92648-5994 | United States |
| Moore UC San Diego Cancer Center /ID# 204919 | La Jolla | California | 92093 | United States |
| United Medical Doctors /ID# 207867 | Los Alamitos | California | 90720-3309 | United States |
| TLC Clinical Research Inc /ID# 216831 | Los Angeles | California | 90048 | United States |
| Gastrointestinal Biosciences Clinical Trials, LLC /ID# 205314 | Los Angeles | California | 90067-2001 | United States |
| Facey Medical Foundation /ID# 205301 | Mission Hills | California | 91345 | United States |
| United Medical Doctors - Murrieta /ID# 205313 | Murrieta | California | 92563 | United States |
| InSite Digestive Health Care - Oxnard /ID# 205628 | Oxnard | California | 93030 | United States |
| Inland Empire Clinical Trials, LLC /ID# 216164 | Rialto | California | 92377 | United States |
| San Diego Clinical Trials /ID# 212122 | San Diego | California | 92120 | United States |
| Medical Assoc Research Grp /ID# 205626 | San Diego | California | 92123 | United States |
| Delta Waves, Inc. /ID# 206170 | Colorado Springs | Colorado | 80918 | United States |
| Western States Clinical Res /ID# 206091 | Wheat Ridge | Colorado | 80033-2896 | United States |
| Western Connecticut Medical Group /ID# 208290 | Danbury | Connecticut | 06810-6000 | United States |
| Gastroenterology Center of CT /ID# 208291 | Hamden | Connecticut | 06518 | United States |
| Gastro Florida /ID# 206174 | Clearwater | Florida | 33756 | United States |
| Universal Axon Clinical Research /ID# 213462 | Doral | Florida | 33166 | United States |
| Palmetto Research, LLC /ID# 208293 | Hialeah | Florida | 33016 | United States |
| Nature Coast Clinical Research - Inverness /ID# 206087 | Inverness | Florida | 34452-4717 | United States |
| Encore Borland-Groover Clinical Research /Id# 208128 | Jacksonville | Florida | 32256 | United States |
| Cfagi Llc /Id# 207995 | Maitland | Florida | 32751-6108 | United States |
| University of Miami /ID# 215445 | Miami | Florida | 33136 | United States |
| Coral Research Clinic /ID# 208292 | Miami | Florida | 33186-4643 | United States |
| Advanced Research Institute, Inc /ID# 206077 | New Port Richey | Florida | 34653 | United States |
| Endoscopic Research, Inc. /ID# 207360 | Orlando | Florida | 32803 | United States |
| Omega Research Consultants /ID# 206066 | Orlando | Florida | 32810 | United States |
| Clinical Research Trials of Florida, Inc. /ID# 206068 | Tampa | Florida | 33607 | United States |
| University of South Florida /ID# 214495 | Tampa | Florida | 33612 | United States |
| AdventHealth Tampa /ID# 207363 | Tampa | Florida | 33613-4680 | United States |
| Gastroenterology Associates of Central Georgia, LLC /ID# 216940 | Macon | Georgia | 31201 | United States |
| Infinite Clinical Trials /ID# 215343 | Riverdale | Georgia | 30274 | United States |
| Atlanta Gastroenterology Spec /ID# 206173 | Suwanee | Georgia | 30024 | United States |
| Next Innovative Clinical Research - Chicago /ID# 217324 | Chicago | Illinois | 60605-2168 | United States |
| The University of Chicago Medical Center /ID# 206172 | Chicago | Illinois | 60637-1443 | United States |
| Carle Foundation Hospital /ID# 207397 | Effingham | Illinois | 62401 | United States |
| MediSphere Medical Research Center /ID# 206073 | Evansville | Indiana | 47714-8011 | United States |
| Indianapolis Gastroenterology /ID# 206381 | Indianapolis | Indiana | 46237 | United States |
| University of Iowa Hospitals and Clinics /ID# 206167 | Iowa City | Iowa | 52242 | United States |
| Cotton-O'Neil Clinical Res Ctr /ID# 206175 | Topeka | Kansas | 66606 | United States |
| Tri-State Gastroenterology /ID# 206124 | Crestview Hills | Kentucky | 41017 | United States |
| Houma Digestive Health Special /ID# 206176 | Houma | Louisiana | 70360 | United States |
| Louisana Research Center, LLC /ID# 206064 | Shreveport | Louisiana | 71105-6800 | United States |
| Gastro Center of Maryland /ID# 206883 | Columbia | Maryland | 21045 | United States |
| University of Michigan Health Systems /ID# 206918 | Ann Arbor | Michigan | 48109 | United States |
| Huron Gastroenterology Assoc /ID# 205109 | Ann Arbor | Michigan | 48197 | United States |
| Clin Res Inst of Michigan, LLC /ID# 207078 | Chesterfield | Michigan | 48047 | United States |
| Revival Research Institute, LLC /ID# 207282 | Southfield | Michigan | 48034-1659 | United States |
| Center for Digestive Health /ID# 207080 | Troy | Michigan | 48098-6363 | United States |
| Mayo Clinic /ID# 205645 | Rochester | Minnesota | 55905-0001 | United States |
| University of Mississippi Medical Center /ID# 213116 | Jackson | Mississippi | 39216-4500 | United States |
| Southern Therapy and Advanced Research (STAR) LLC /ID# 206069 | Jackson | Mississippi | 39216 | United States |
| Las Vegas Medical Research /ID# 206814 | Las Vegas | Nevada | 89113 | United States |
| AGA Clinical Research Associates, LLC /ID# 206880 | Egg Harbor | New Jersey | 08234 | United States |
| Atlantic Digestive Health Inst /ID# 208748 | Morristown | New Jersey | 07960 | United States |
| Rutgers Robert Wood Johnson /ID# 207382 | New Brunswick | New Jersey | 08901 | United States |
| University of New Mexico Department of Internal Medicine /ID# 214397 | Albuquerque | New Mexico | 87131-0001 | United States |
| NY Scientific /ID# 206080 | Brooklyn | New York | 11235 | United States |
| NYU Langone Long Island Clinical Research Associates /ID# 206079 | Lake Success | New York | 11042 | United States |
| DiGiovanna Institute for Medical Education & Research /ID# 206885 | North Massapequa | New York | 11758 | United States |
| Premier Medical Group - GI Division /ID# 206097 | Poughkeepsie | New York | 12601 | United States |
| Gastro Group of Rochester /ID# 206881 | Rochester | New York | 14618-5703 | United States |
| Richmond University Medical Center /ID# 213185 | Staten Island | New York | 10310-1664 | United States |
| Advantage Clinical Trials /ID# 206082 | The Bronx | New York | 10468 | United States |
| Digestive Health Partners, P.A /ID# 206842 | Asheville | North Carolina | 28801 | United States |
| Atrium Health Carolinas Medical Center /ID# 206085 | Charlotte | North Carolina | 28203 | United States |
| Charlotte Gastroenterology and Hepatology, PLLC /ID# 206138 | Charlotte | North Carolina | 28207 | United States |
| Wake Forest Baptist Medical Center /ID# 206067 | Winston-Salem | North Carolina | 27157-0001 | United States |
| Duplicate_Plains Clinical Research Center, LLC /ID# 205111 | Fargo | North Dakota | 58104 | United States |
| University of Cincinnati /ID# 205633 | Cincinnati | Ohio | 45267-0585 | United States |
| The Ohio State University /ID# 205637 | Columbus | Ohio | 43210 | United States |
| Optimed Research, Ltd. /ID# 205638 | Columbus | Ohio | 43235 | United States |
| Hometown Urgent Care and Resea /ID# 205630 | Dayton | Ohio | 45424 | United States |
| Dayton Gastroenterology, Inc. /ID# 205639 | Englewood | Ohio | 45415 | United States |
| Great Lakes Gastroenterology Research LLC /ID# 205631 | Mentor | Ohio | 44060-6211 | United States |
| Hightower Clinical /ID# 216336 | Oklahoma City | Oklahoma | 73102 | United States |
| Digestive Disease Specialists /ID# 206076 | Oklahoma City | Oklahoma | 73112 | United States |
| Options Health Research, LLC /ID# 206707 | Tulsa | Oklahoma | 74104 | United States |
| Healthcare Research Consultant /ID# 206706 | Tulsa | Oklahoma | 74135 | United States |
| Guthrie Medical Group, PC /ID# 206078 | Sayre | Pennsylvania | 18840 | United States |
| Pharmacorp Clinical Trials /ID# 206074 | Charleston | South Carolina | 29412 | United States |
| Gastroenterology Associates, P.A. of Greenville /ID# 206098 | Greenville | South Carolina | 29615-3593 | United States |
| Gastro One /ID# 206178 | Germantown | Tennessee | 38138 | United States |
| East Tennessee Research Institute /ID# 206169 | Johnson City | Tennessee | 37604 | United States |
| Quality Medical Research /ID# 206088 | Nashville | Tennessee | 37211 | United States |
| Vanderbilt University Medical Center /ID# 210405 | Nashville | Tennessee | 37232-0011 | United States |
| TX Clinical Research Institute /ID# 206718 | Arlington | Texas | 76012 | United States |
| Inquest Clinical Research /ID# 206132 | Baytown | Texas | 77521 | United States |
| Texas Digestive Disease Consultants /ID# 209805 | Cedar Park | Texas | 78613-5028 | United States |
| Texas Digestive Disease Consultants /ID# 209948 | Cedar Park | Texas | 78613-5028 | United States |
| Baylor Scott & White Center for Inflammatory Bowel Diseases /ID# 207484 | Dallas | Texas | 75246 | United States |
| DHAT Research Institute /ID# 206716 | Garland | Texas | 75044-2208 | United States |
| Vilo Research Group Inc /ID# 212625 | Houston | Texas | 77017-2337 | United States |
| Baylor College of Medicine - Baylor Medical Center /ID# 206717 | Houston | Texas | 77030-3411 | United States |
| Centex Studies, Inc. - Houston /ID# 206168 | Houston | Texas | 77058 | United States |
| GI Specialists of Houston /ID# 206090 | Houston | Texas | 77070-4347 | United States |
| Caprock Gastro Research /ID# 215115 | Lubbock | Texas | 79424-3017 | United States |
| Clinical Associates in Research Therapeutics of America, LLC /ID# 206710 | San Antonio | Texas | 78212 | United States |
| Southern Star Research Institute, LLC /ID# 205379 | San Antonio | Texas | 78229-5390 | United States |
| Baylor Scott & White Center for Diagnostic Medicine /ID# 206096 | Temple | Texas | 76508 | United States |
| Duplicate_Tyler Research Institue /ID# 206075 | Tyler | Texas | 75701 | United States |
| Gastro Health & Nutrition - Victoria /ID# 205378 | Victoria | Texas | 77904 | United States |
| Advanced Research Institute /ID# 206133 | Ogden | Utah | 84403 | United States |
| Ctr for Gastrointestinal Healt /ID# 208475 | Franklin | Virginia | 23851 | United States |
| Washington Gastroenterology Associates /ID# 206177 | Bellevue | Washington | 98004 | United States |
| Virginia Mason - Seattle Orthapedics /ID# 206070 | Seattle | Washington | 98101 | United States |
| The Vancouver Clinic, INC. PS /ID# 204973 | Vancouver | Washington | 98664 | United States |
| Wisconsin Center for Advanced Research, a division of GI Associates, LLC /ID# 206917 | Milwaukee | Wisconsin | 53215 | United States |
| Froedtert Memorial Lutheran Hospital /ID# 206945 | Milwaukee | Wisconsin | 53226-3522 | United States |
| Cardio Alem /ID# 211282 | San Isidro | Buenos Aires | 1642 | Argentina |
| Mautalen Salud e Investigacion /ID# 206033 | Ciudad Autonoma de Buenos Aire | Ciuadad Autonoma de Buenos Aires | 1128 | Argentina |
| Hospital Britanico de Buenos Aires /ID# 209497 | Ciudad Autonoma de Buenos Aire | Ciuadad Autonoma de Buenos Aires | 1280 | Argentina |
| Gedyt /ID# 210017 | Ciudad Autonoma de Buenos Aire | Ciuadad Autonoma de Buenos Aires | 1426 | Argentina |
| Hospital Privado Univesitario /ID# 206030 | Córdoba | 5016 | Argentina |
| Macquarie University Hospital /ID# 211955 | Macquarie University | New South Wales | 2109 | Australia |
| Duplicate_Mater Misericordiae /ID# 212687 | South Brisbane | Queensland | 4101 | Australia |
| Griffith University /ID# 211956 | Southport | Queensland | 4222 | Australia |
| St Vincent's Hospital Melbourne /ID# 205758 | Fitzroy | Victoria | 3065 | Australia |
| Monash Medical Centre /ID# 206486 | Melbourne | Victoria | 3168 | Australia |
| Fiona Stanley Hospital /ID# 211642 | Murdoch | Western Australia | 6150 | Australia |
| Klinik Landstrasse /ID# 205764 | Vienna | State of Vienna | 1030 | Austria |
| Medical University of Vienna /ID# 205763 | Vienna | State of Vienna | 1090 | Austria |
| LKH Salzburg and Paracelsus /ID# 208788 | Salzburg | 5020 | Austria |
| Universitair Ziekenhuis Leuven /ID# 205988 | Leuven | Vlaams-Brabant | 3000 | Belgium |
| AZ Maria Middelares /ID# 210928 | Ghent | 9000 | Belgium |
| University Clinical Centre of the Republic of Srpska /ID# 208053 | Banja Luka | Republika Srpska | 78000 | Bosnia and Herzegovina |
| University Clinical Centre of the Republic of Srpska /ID# 208055 | Banja Luka | Republika Srpska | 78000 | Bosnia and Herzegovina |
| University Clinical Center Tuzla /ID# 208057 | Tuzla | Tuzlanski | 75000 | Bosnia and Herzegovina |
| University Clinical Hospital Mostar /ID# 208054 | Mostar | 88000 | Bosnia and Herzegovina |
| Clinical Center University of Sarajevo /ID# 208058 | Sarajevo | 71000 | Bosnia and Herzegovina |
| Hospital Nossa Senhora das Graças /ID# 206981 | Curitiba | Paraná | 80810-040 | Brazil |
| Hospital de Clinicas de Porto Alegre /ID# 206985 | Porto Alegre | Rio Grande do Sul | 90035-903 | Brazil |
| Upeclin Fmb - Unesp /Id# 206986 | Botucatu | São Paulo | 18618-686 | Brazil |
| Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto - USP /ID# 206504 | Ribeirão Preto | São Paulo | 14051-140 | Brazil |
| Faculdade de Medicina do ABC /ID# 206984 | Santo André | São Paulo | 09060-870 | Brazil |
| Kaiser Clinica e Hospital Dia /ID# 206982 | São José do Rio Preto | São Paulo | 15015-110 | Brazil |
| University of Calgary - Cumming School of Medicine - Adult Cystic Fibrosis Clini /ID# 205755 | Calgary | Alberta | T2N 4Z6 | Canada |
| Allen Whey Khye Lim Professional Corporation /ID# 211167 | Edmonton | Alberta | T5R 1W2 | Canada |
| Covenant Health /ID# 205500 | Edmonton | Alberta | T6K 4B2 | Canada |
| Percuro Clinical Research, Ltd /ID# 205501 | Victoria | British Columbia | V8V 3M9 | Canada |
| Duplicate_Toronto Digestive Disease Asso /ID# 205498 | Vaughan | Ontario | L4L 4Y7 | Canada |
| Crchum /Id# 207387 | Montreal | Quebec | H2X 0A9 | Canada |
| CIUSSS de l'Estrie - CHUS /ID# 205499 | Sherbrooke | Quebec | J1G 2E8 | Canada |
| Research Group /ID# 208037 | Santiago | Santiago Metropolitan | 2540364 | Chile |
| M y F Estudios Clínicos Ltda. /ID# 208035 | Santiago | Santiago Metropolitan | 7750495 | Chile |
| Hospital Guillermo Grant Benavente de Concepción /ID# 212426 | Concepción | 4070038 | Chile |
| CTR Estudios Clinicos /ID# 208036 | Providencia | 7500571 | Chile |
| Hospital Clinico Universidad De Los Andes /ID# 207426 | Santiago | 7501504 | Chile |
| Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 205267 | Guangzhou | Guangdong | 510120 | China |
| The Sixth Affiliated Hosp Sun /ID# 205268 | Guangzhou | Guangdong | 510655 | China |
| Affiliated Taihe Hospital of Hubei University of Medicine /ID# 216406 | Shiyan | Hubei | 442700 | China |
| Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 205266 | Wuhan | Hubei | 430022 | China |
| The First Affiliated Hospital of Nanchang University /ID# 212186 | Nanchang | Jiangxi | 330006 | China |
| The First Hospital of Jilin University /ID# 210088 | Changchun | Jilin | 130021 | China |
| Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 205333 | Shanghai | Shanghai Municipality | 200025 | China |
| The second Affiliated hospital of Zhejiang University school of Medicine /ID# 205271 | Hangzhou | Zhejiang | 310009 | China |
| West China Hospital, Sichuan University /ID# 205332 | Chengdu | 610041 | China |
| Duplicate_Tianjin Med Univ General Hosp /ID# 205246 | Tianjin | 300052 | China |
| Tongji Hospital Tongji Medical College Huazhong University of Science and Techno /ID# 205265 | Wuhan | 430030 | China |
| Corporacion Hospitalaria Juan Cuidad Sede Denominada Hospital Universitario Mayo /ID# 208886 | Bogota DC | Cundinamarca | 111221 | Colombia |
| Instituto Medico de Alta Tecnologia Oncomédica S.A /ID# 208887 | Montería | Departamento de Córdoba | 230002 | Colombia |
| Hospital Universitario San Vic /ID# 208888 | Medellín | 50010 | Colombia |
| Klinicka bolnica Dubrava Zagreb /ID# 208460 | Zagreb | City of Zagreb | 10000 | Croatia |
| Poliklinika Solmed /ID# 211568 | Zagreb | City of Zagreb | 10000 | Croatia |
| Klinicki bolnicki centar Rijeka /ID# 208650 | Rijeka | Primorje-Gorski Kotar County | 51000 | Croatia |
| Klinicki bolnicki centar Split /ID# 217027 | Split | 21000 | Croatia |
| Hepato-Gastroenterologie HK, s.r.o. /ID# 205672 | Hradec Králové | 500 12 | Czechia |
| CTCenter MaVe s.r.o. /ID# 205671 | Olomouc | 779 00 | Czechia |
| Artroscan s.r.o. /ID# 205668 | Ostrava | 722 00 | Czechia |
| Nemocnice Pardubickeho kraje, a.s. /ID# 213540 | Pardubice | 530 03 | Czechia |
| Nemocnice Milosrdnych sester sv. Karla Boromejskeho v Praze /ID# 216223 | Prague | 118 33 | Czechia |
| Axon Clinical, s.r.o. /ID# 205670 | Prague | 140 00 | Czechia |
| ISCARE a.s. /ID# 209240 | Prague | 190 00 | Czechia |
| East Tallinn Central Hospital /ID# 207564 | Tallinn | Harju | 10138 | Estonia |
| West Tallinn Central Hospital /ID# 207356 | Tallinn | 10617 | Estonia |
| North Estonia Medical Centre /ID# 207357 | Tallinn | 13419 | Estonia |
| Tartu University Hospital /ID# 212282 | Tartu | 51014 | Estonia |
| Tampere University Hospital /ID# 206161 | Tampere | Pirkanmaa | 33520 | Finland |
| Keski-Suomen Sairaala Nova /ID# 206159 | Jyväskylä | 40620 | Finland |
| Laakarikeskus Ikioma /ID# 205814 | Mikkeli | 50100 | Finland |
| Tyks /Id# 205813 | Turku | 20521 | Finland |
| Chu de Nice-Hopital L'Archet Ii /Id# 209118 | Nice | Alpes-Maritimes | 06202 | France |
| Centre Hospitalier Lyon Sud /ID# 209121 | Pierre-Bénite | Rhone | 69495 | France |
| Universitatsklinikum Mannheim /ID# 206811 | Mannheim | Baden-Wurttemberg | 68167 | Germany |
| Duplicate_Universitaetsklinikum Tuebingen /ID# 206737 | Tübingen | Baden-Wurttemberg | 72076 | Germany |
| Gastroenterologische Gemeinschaftspraxis Herne /ID# 214576 | Herne | North Rhine-Westphalia | 44623 | Germany |
| Zentrum für Gastroenterologie Saar MVZ GmbH /ID# 215813 | Saarbrücken | Saarland | 66111 | Germany |
| Duplicate_Praxis am Bayrischen Platz /ID# 206733 | Berlin | 10825 | Germany |
| Agaplesion Markus Krankenhaus /ID# 206731 | Frankfurt am Main | 60431 | Germany |
| Duplicate_Univ Hosp Schleswig-Holstein /ID# 206791 | Kiel | 24105 | Germany |
| Medizinisches Versorgungszentrum Portal 10 /ID# 207137 | Münster | 48155 | Germany |
| General Hospital of Athens Laiko /ID# 208671 | Athens | Attica | 11527 | Greece |
| University General Hospital of Heraklion PA.G.N.I /ID# 207061 | Heraklion | Crete | 711 10 | Greece |
| General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 206332 | Athens | 10676 | Greece |
| Duplicate_General Hospital of Thessaloniki Hippokrateio /ID# 208822 | Thessaloniki | 54642 | Greece |
| Bekes Megyei Kozponti Korhaz /ID# 205885 | Békéscsaba | 5600 | Hungary |
| Semmelweis Egyetem /ID# 205883 | Budapest | 1085 | Hungary |
| Soproni Erzsebet Oktato Korhaz es Rehabilitacios Intezet /ID# 207992 | Sopron | 9400 | Hungary |
| Mentahaz Maganorvosi Kozpont /ID# 205882 | Székesfehérvár | 8000 | Hungary |
| Beaumont Hospital /ID# 206509 | Dublin | D09 XR63 | Ireland |
| University Hospital Galway /ID# 218035 | Galway | H91 YR71 | Ireland |
| Rambam Health Care Campus /ID# 206362 | Haifa | 3109601 | Israel |
| Shaare Zedek Medical Center /ID# 206365 | Jerusalem | 91031 | Israel |
| A.O.U. Policlinico S.Orsola-Malpighi /ID# 206351 | Bologna | Emilia-Romagna | 40138 | Italy |
| ASST Rhodense/Presidio Ospedaliero di Rho /ID# 216611 | Rho | Milano | 20017 | Italy |
| Istituto Clinico Humanitas /ID# 206346 | Rozzano | Milano | 20089 | Italy |
| Presidio Columbus-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Un /ID# 206347 | Rome | Roma | 00168 | Italy |
| IRCCS Ospedale Sacro Cuore Don Calabria /ID# 206354 | Negrar | Verona | 37024 | Italy |
| Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 206349 | Milan | 20122 | Italy |
| A.O. Ospedali Riuniti Villa Sofia - Cervello /ID# 206350 | Palermo | 90146 | Italy |
| Nagoya University Hospital /ID# 206355 | Nagoya | Aichi-ken | 4668560 | Japan |
| Nagoya City University Hospital /ID# 206058 | Nagoya | Aichi-ken | 467-8602 | Japan |
| Toyohashi Municipal Hospital /ID# 207625 | Toyohashi | Aichi-ken | 441-8570 | Japan |
| Ieda Hospital /ID# 207479 | Toyota-shi | Aichi-ken | 470-1219 | Japan |
| Hirosaki National Hospital /ID# 206387 | Hirosaki-shi | Aomori | 036-8545 | Japan |
| Tokatsu Tsujinaka Hospital /ID# 214963 | Abiko-shi | Chiba | 270-1168 | Japan |
| Tsujinaka Hospital Kashiwanoha /ID# 209573 | Kashiwa-shi | Chiba | 277-0871 | Japan |
| Toho University Medical Center Sakura Hospital /ID# 207705 | Sakura-shi | Chiba | 285-8741 | Japan |
| Juntendo University Urayasu Hospital /ID# 208784 | Urayasu-shi | Chiba | 279-0021 | Japan |
| Fukui Prefectural Hospital /ID# 210449 | Fukui-shi | Fukui | 910-8526 | Japan |
| Fukuoka University Chikushi Hospital /ID# 214405 | Chikushino-shi | Fukuoka | 818-8502 | Japan |
| Saiseikai Fukuoka Genaral Hospital /ID# 209482 | Fukuoka | Fukuoka | 810-0001 | Japan |
| Kurume University Hospital /ID# 206385 | Kurume-shi | Fukuoka | 830-0011 | Japan |
| Ogaki Municipal Hospital /ID# 208227 | Ogaki-shi | Gifu | 503-8502 | Japan |
| NHO Fukuyama Medical Center /ID# 206295 | Fukuyama-shi | Hiroshima | 720-8520 | Japan |
| Hiroshima University Hospital /ID# 206464 | Hiroshima | Hiroshima | 734-8551 | Japan |
| Asahikawa Medical University Hospital /ID# 206404 | Midorigaokahiga-shi | Hokkaido | 078-8510 | Japan |
| Obihiro kosei Hospital /ID# 210424 | Obihiro-shi | Hokkaido | 080-0024 | Japan |
| Sapporo Tokushukai Hospital /ID# 209448 | Sapporo | Hokkaido | 004-0041 | Japan |
| Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 206059 | Sapporo | Hokkaido | 060-0033 | Japan |
| Sapporo Medical University Hospital /ID# 206314 | Sapporo | Hokkaido | 060-8543 | Japan |
| Sapporo Higashi Tokushukai Hospital /ID# 208494 | Sapporo | Hokkaido | 065-0033 | Japan |
| Aoyama Clinic /ID# 206452 | Kobe | Hyōgo | 650-0015 | Japan |
| Hyogo College of Medicine Hospital /ID# 206455 | Nishinomiya-shi | Hyōgo | 663-8501 | Japan |
| Kanazawa University Hospital /ID# 206316 | Kanazawa | Ishikawa-ken | 920-8641 | Japan |
| Iwate Medical University Uchimaru Medical Center /ID# 207051 | Morioka | Iwate | 020-8505 | Japan |
| Idzuro Imamura Hospital /ID# 207639 | Kagoshima | Kagoshima-ken | 892-0824 | Japan |
| Sameshima Hospital /ID# 207935 | Kagoshima | Kagoshima-ken | 892-0846 | Japan |
| St. Marianna University School of Medicine Hospital /ID# 209451 | Kawasaki-shi | Kanagawa | 216-8511 | Japan |
| Showa University Fujigaoka Hospital /ID# 208224 | Yokohama | Kanagawa | 227-8501 | Japan |
| Kyoto University Hospital /ID# 211809 | Kyoto | Kyoto | 606-8507 | Japan |
| Mie University Hospital /ID# 206803 | Tsu | Mie-ken | 514-8507 | Japan |
| Yokkaichi Hazu Medical Center /ID# 214348 | Yokkaichi-shi | Mie-ken | 510-0016 | Japan |
| National Hospital Organization Sendai Medical Center /ID# 209528 | Sendai | Miyagi | 983-8520 | Japan |
| NHO Nagasaki Medical Center /ID# 210822 | Omura-shi | Nagasaki | 856-8562 | Japan |
| Kenseikai Dongo Hospital /ID# 208101 | Yamatotakada-shi | Nara | 635-0022 | Japan |
| Saiseikai Niigata Hospital /ID# 209921 | Niigata | Niigata | 950-1104 | Japan |
| Niigata University Medical & Dental Hospital /ID# 218049 | Niigata | Niigata | 951-8520 | Japan |
| Ishida Clinic of IBD and Gastroenterology /ID# 210119 | Ōita | Oita Prefecture | 870-0823 | Japan |
| Chikuba Hospital for Proctological and Gastrointestinal Diseases /ID# 206646 | Kurashiki-shi | Okayama-ken | 710-0142 | Japan |
| Okayama University Hospital /ID# 217925 | Okayama | Okayama-ken | 700-8558 | Japan |
| Kinshukai Infusion Clinic /ID# 207865 | Osaka | Osaka | 530-0011 | Japan |
| Kitano Hospital /ID# 210397 | Osaka | Osaka | 530-8480 | Japan |
| Japanese Red Cross Osaka Hospital /ID# 209478 | Osaka | Osaka | 543-8555 | Japan |
| Osaka City University Hospital /ID# 206457 | Osaka | Osaka | 545-8586 | Japan |
| Toyonaka Municipal Hospital /ID# 217082 | Toyonaka-shi | Osaka | 560-0055 | Japan |
| Saga University Hospital /ID# 209270 | Saga | Saga-ken | 849-8501 | Japan |
| Saitama Medical Center /ID# 206393 | Kawagoe-shi | Saitama | 350-8550 | Japan |
| Tokitokai Tokito clinic /ID# 206313 | Saitama-shi | Saitama | 336-0963 | Japan |
| National Hospital Organization Higashi-Ohmi General Medical Center /ID# 210710 | Higashi-ohmi-shi | Shiga | 527-8505 | Japan |
| Shimane University School of Medicine /ID# 208905 | Izumo-shi | Shimane | 693-0021 | Japan |
| Hamamatsu University Hospital /ID# 206459 | Hamamatsu | Shizuoka | 431-3192 | Japan |
| NHO Shizuoka Medical Center /ID# 208785 | Sunto-gun | Shizuoka | 411-8611 | Japan |
| Tokyo Medical And Dental University, Medical Hospital /ID# 206453 | Bunkyo-ku | Tokyo | 113-8519 | Japan |
| St.Luke's International Hospital /ID# 208076 | Chuo-ku | Tokyo | 104-8560 | Japan |
| Tokai University Hachioji Hospital /ID# 208903 | Hachioji-shi | Tokyo | 192-0032 | Japan |
| Teikyo University Hospital /ID# 209866 | Itabashi-ku | Tokyo | 173-8606 | Japan |
| Center Hospital of the National Center for Global Health and Medicine /ID# 209532 | Shinjuku-ku | Tokyo | 162-8655 | Japan |
| Tokyo Women's Medical University Hospital /ID# 206460 | Shinjuku-ku | Tokyo | 162-8666 | Japan |
| Yamagata University Hospital /ID# 206465 | Yamagata | Yamagata | 990-9585 | Japan |
| Tokuyama Central Hospital /ID# 216994 | Shunan-shi | Yamaguchi | 745-8522 | Japan |
| Shoyukai Fujita Gastroenterological Hospital /ID# 216493 | Takatsuki-shi | 569-0086 | Japan |
| Riga East Clinical Univ Hosp /ID# 206828 | Riga | 1038 | Latvia |
| P. Stradins Clinical Univ Hosp /ID# 206827 | Riga | LV-1002 | Latvia |
| Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 209052 | Kaunas | 50161 | Lithuania |
| Klaipeda Seamens Hospital /ID# 208791 | Klaipėda | 92288 | Lithuania |
| Klaipeda University Hospital /ID# 208790 | Klaipėda | 92288 | Lithuania |
| Vilnius University Hospital /ID# 209051 | Vilnius | LT-08661 | Lithuania |
| Universiti Kebangsaan Malaysia (UKM) Medical Centre /ID# 207662 | Kuala Lumpur | Selangor | 56000 | Malaysia |
| Duplicate_Uni Malaya MC /ID# 208936 | Kuala Lumpur | 59100 | Malaysia |
| Morales Vargas Centro de Investigacion S.C. /ID# 211326 | León | Guanajuato | 37000 | Mexico |
| Clinica de Investigacion en Reumatologia y Obesidad S.C. /ID# 208068 | Guadalajara | Jalisco | 44650 | Mexico |
| Centro Regiomontano de Estudios Clínicos ROMA S.C /ID# 208067 | Monterrey | Nuevo León | 64610 | Mexico |
| Erasmus Medisch Centrum /ID# 205280 | Rotterdam | 3015 GD | Netherlands |
| Akershus Universitetssykehus_MAIN /ID# 205293 | Lorenskog | Akershus | 1478 | Norway |
| Universitetssykehuset Nord-Norge /ID# 205691 | Tromsø | Troms | 9019 | Norway |
| Gastromed /Id# 216108 | Torun | Kuyavian-Pomeranian Voivodeship | 87-100 | Poland |
| Centrum Zdrowia MDM /ID# 205874 | Warsaw | Masovian Voivodeship | 00-635 | Poland |
| Centrum Medyczne Reuma Park w Warszawie /ID# 212913 | Warsaw | Masovian Voivodeship | 02-691 | Poland |
| NZOZ Vivamed /ID# 216697 | Warsaw | Masovian Voivodeship | 03-580 | Poland |
| Instytut Pomnik - Centrum Zdrowia Dziecka /ID# 215070 | Warsaw | Masovian Voivodeship | 04-730 | Poland |
| Endoskopia Sp. z o.o. /ID# 212964 | Sopot | Pomeranian Voivodeship | 81-756 | Poland |
| Hospital da Senhora da Oliveira Guimaraes, EPE /ID# 205554 | Guimarães | Braga District | 4835-044 | Portugal |
| Centro Hospitalar de Entre Douro e Vouga /ID# 205563 | Santa Maria DA Feira | Porto District | 4520-211 | Portugal |
| Unidade Local de Saúde do Alto Minho, EPE - Hospital Conde de Bertiandos /ID# 205556 | Ponte de Lima | Viana do Castelo District | 4990-041 | Portugal |
| Hospital Garcia de Orta, EPE /ID# 206143 | Almada | 2805-267 | Portugal |
| CCA Braga - Hospital de Braga /ID# 206144 | Braga | 4710-243 | Portugal |
| Hospital Santo Antonio dos Cap /ID# 206145 | Lisbon | 1150-069 | Portugal |
| Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 206117 | Lisbon | 1649-035 | Portugal |
| Centro Hospitalar Universitario de Sao Joao, EPE /ID# 206142 | Porto | 4200-319 | Portugal |
| School of Medicine University of Puerto Rico-Medical Science Campus /ID# 209626 | San Juan | 00935 | Puerto Rico |
| Immanuel Kant Baltic Federal University /ID# 208264 | Kaliningrad | Kaliningrad Oblast | 236016 | Russia |
| NW State Medical Univ na Mechn /ID# 208258 | Saint Petersburg | Leningradskaya Oblast' | 191015 | Russia |
| Perm Clinical Center of the Federal Medical and Biological Agency /ID# 211653 | Perm | Permskiy Kray | 614109 | Russia |
| Medical Company Hepatolog /ID# 208261 | Samara | Samara Oblast | 443063 | Russia |
| Professor Pasechnikov Gastroenterology and Pankreatology clinic /ID# 211652 | Stavropol | Stavropol Kray | 355012 | Russia |
| Kazan State Medical University /ID# 208256 | Kazan' | Tatarstan, Respublika | 420012 | Russia |
| Olla-Med Clinic /ID# 215335 | Moscow | 105554 | Russia |
| Republican hospital named after V.A. Baranov /ID# 206507 | Petrozavodsk | 185019 | Russia |
| Euromedservice /ID# 208265 | Pushkin | 196603 | Russia |
| LLC Novaya Clinica /ID# 208260 | Pyatigorsk | 357532 | Russia |
| Clinical Hosp Center Zvezdara /ID# 205258 | Belgrade | Beograd | 11000 | Serbia |
| Military Medical Academy /ID# 205257 | Belgrade | Beograd | 11000 | Serbia |
| University Clinical Center Serbia /ID# 205256 | Belgrade | Beograd | 11000 | Serbia |
| Clin Hosp Ctr Bezanijska Kosa /ID# 206413 | Belgrade | Beograd | 11080 | Serbia |
| University Clinical Center of Nis /ID# 206411 | Niš | Nisavski Okrug | 18000 | Serbia |
| University Clinical Center Kragujevac /ID# 206410 | Kragujevac | Sumadijski Okrug | 34000 | Serbia |
| Clinical Center Vojvodina /ID# 205259 | Novi Sad | Vojvodina | 21000 | Serbia |
| General Hospital Leskovac /ID# 217881 | Leskovac | 16000 | Serbia |
| National University Hospital /ID# 209099 | Singapore | 119074 | Singapore |
| Gleneagles Medical Centre /ID# 206954 | Singapore | 258499 | Singapore |
| Tan Tock Seng Hospital /ID# 207663 | Singapore | 308433 | Singapore |
| Medak s.r.o. /ID# 205191 | Bratislava | Bratislava Region | 851 01 | Slovakia |
| Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 205147 | Banská Bystrica | 975 17 | Slovakia |
| B+B MED, s.r.o. /ID# 205213 | Košice | 040 01 | Slovakia |
| Fakultna nemocnica s poliklini /ID# 211372 | Nové Zámky | 940 34 | Slovakia |
| GASTRO I., s.r.o. /ID# 205148 | Prešov | 080 01 | Slovakia |
| MD Search /ID# 208084 | Boksburg North | Gauteng | 1460 | South Africa |
| Clinresco Centers /ID# 208083 | Johannesburg | Gauteng | 1619 | South Africa |
| Lenasia Clinical Trial Centre /ID# 214359 | Johannesburg | Gauteng | 1820 | South Africa |
| Wits Clinical Research , Wits Health Consortium (PTY) Ltd /ID# 208082 | Johannesburg | Gauteng | 2193 | South Africa |
| Wits Clinical Research Site /ID# 208949 | Johannesburg | Gauteng | 2193 | South Africa |
| Kingsbury Hospital /ID# 205281 | Cape Town | Western Cape | 7708 | South Africa |
| Private Practice Dr MN Rajabally /ID# 205273 | Cape Town | Western Cape | 7800 | South Africa |
| Mediclinic Milnerton /ID# 207979 | CAPE TOWN Milnerton | Western Cape | 7441 | South Africa |
| Kangbuk Samsung Hospital /ID# 206960 | Seoul | Seoul Teugbyeolsi | 03181 | South Korea |
| Dong-A University Hospital /ID# 206955 | Busan | 49201 | South Korea |
| Pusan National University Hospital /ID# 206956 | Busan | 49241 | South Korea |
| Yeungnam University Medical Center /ID# 206959 | Daegu | 42415 | South Korea |
| Duplicate_CHA Bundang Medical Center /ID# 207432 | Seongnam-si, Gyeonggi-do | 13496 | South Korea |
| Yonsei University Health System, Severance hospital /ID# 206958 | Seoul | 03722 | South Korea |
| Hospital Clínico Universitario de Santiago-CHUS /ID# 204411 | Santiago de Compostela | A Coruna | 15706 | Spain |
| Hospital Unversitario Marques de Valdecilla /ID# 216622 | Santander | Cantabria | 39008 | Spain |
| Hospital Universitario Dr. Negrin /ID# 206905 | Las Palmas de Gran Canaria | Las Palmas | 35010 | Spain |
| Hospital Universitario A Coruna - CHUAC /ID# 206907 | A Coruña | 15006 | Spain |
| Hospital Clinic de Barcelona /ID# 206906 | Barcelona | 08036 | Spain |
| Hospital Universitario Reina Sofia /ID# 204412 | Córdoba | 14004 | Spain |
| Hospital Universitario Ramon y Cajal /ID# 204410 | Madrid | 28034 | Spain |
| Hospital Universitario La Paz /ID# 214540 | Madrid | 28046 | Spain |
| Hospital Clinico Universitario de Salamanca /ID# 205013 | Salamanca | 37007 | Spain |
| Hospital Universitario y Politecnico La Fe /ID# 206904 | Valencia | 46026 | Spain |
| Kantonsspital St. Gallen /ID# 211310 | Sankt Gallen | Canton of St. Gallen | 9007 | Switzerland |
| Universitaetsspital Basel /ID# 211381 | Basel | 4031 | Switzerland |
| Inselspital, Universitaetsklinik /ID# 211312 | Bern | 3010 | Switzerland |
| Universitaetsspital Zuerich /ID# 211308 | Zurich | 8091 | Switzerland |
| China Medical University Hosp /ID# 207845 | Taichung | Taichung | 40447 | Taiwan |
| National Taiwan University Hospital /ID# 207847 | Taipei City | Taipei | 100 | Taiwan |
| Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 207848 | Kaohsiung City | 80708 | Taiwan |
| Taipei Veterans General Hosp /ID# 207849 | Taipei | 11217 | Taiwan |
| Erciyes University Medical Fac /ID# 207506 | Melikgazi | Kayseri | 38030 | Turkey (Türkiye) |
| Gazi University Med. Faculty /ID# 208040 | Ankara GAZI | 06500 | Turkey (Türkiye) |
| Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty /ID# 207507 | Istanbul | 34098 | Turkey (Türkiye) |
| Umraniye Training and Res Hosp /ID# 208206 | Istanbul | 34764 | Turkey (Türkiye) |
| Mersin University Medical /ID# 208039 | Mersin | 33343 | Turkey (Türkiye) |
| Communal Non-Commercial Enterprize of Kharkiv Regional Council Regional Clinical /ID# 206939 | Kharkiv | Kharkiv Oblast | 61204 | Ukraine |
| Kyiv Regional Hospital /ID# 217373 | Kyiv | Kyivska Oblast | 04073 | Ukraine |
| PE PMC Acinus, Medical and Diagnostic Center /ID# 217218 | Kropyvnytskyi | 25006 | Ukraine |
| Medical centre of CONSILIUM MEDICAL LLC /ID# 217447 | Kyiv | 04050 | Ukraine |
| Vinnytsia Regional Clinical Hospital n.a. M.I.Pyrogov /ID# 216300 | Vinnytsia | 21018 | Ukraine |
| Basingstoke & North Hampshire /ID# 207985 | Basingstoke | RG24 9NA | United Kingdom |
| Queen Elizabeth University Hos /ID# 205154 | Glasgow | G514TF | United Kingdom |
| Huddersfield Royal Infirmary /ID# 217660 | Huddersfield | HD3 3EA | United Kingdom |
| St. George's Healthcare NHS /ID# 208375 | London | SW17 0QT | United Kingdom |
| Barts and the London NHS Trust /ID# 205153 | Whitechapel | E1 1 BB | United Kingdom |
| Derived |
| Panes J, Dubinsky MC, Ishiguro Y, Shukla N, Dubcenco E, Remple V, Sharma D, Panaccione R. Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data. J Crohns Colitis. 2025 Jul 3;19(7):jjaf095. doi: 10.1093/ecco-jcc/jjaf095. |
| 38010661 | Derived | Panaccione R, Danese S, Zhou W, Klaff J, Ilo D, Yao X, Levy G, Higgins PDR, Loftus EV Jr, Chen S, Gonzalez YS, Leonard C, Hebuterne X, Lindsay JO, Cao Q, Nakase H, Colombel JF, Vermeire S. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2024 Feb;59(3):393-408. doi: 10.1111/apt.17816. Epub 2023 Nov 27. |
| 37942921 | Derived | Raine T, Ishiguro Y, Rubin DT, Finney-Hayward T, Vladea R, Liu J, Phillips C, Cheng E, Targownik L, Loftus EV Jr. Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme. J Crohns Colitis. 2024 May 31;18(5):695-707. doi: 10.1093/ecco-jcc/jjad190. |
| 36790041 | Derived | Danese S, Tran J, D'Haens G, Rubin DT, Aoyama N, Zhou W, Ilo D, Yao X, Sanchez Gonzalez Y, Panaccione R. Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data. Inflamm Bowel Dis. 2023 Nov 2;29(11):1723-1729. doi: 10.1093/ibd/izad016. |
| 36645051 | Derived | Panes J, Loftus EV, Higgins PDR, Lindsay JO, Zhou W, Yao X, Ilo D, Phillips C, Tran J, Sanchez Gonzalez Y, Vermeire S. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results. Inflamm Bowel Dis. 2023 Sep 1;29(9):1421-1430. doi: 10.1093/ibd/izac260. |
| 36571701 | Derived | Ponce-Bobadilla AV, Stodtmann S, Eckert D, Zhou W, Liu W, Mohamed MF. Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients. Clin Pharmacokinet. 2023 Jan;62(1):101-112. doi: 10.1007/s40262-022-01191-6. Epub 2022 Dec 26. |
| 36464141 | Derived | Loftus EV Jr, Colombel JF, Takeuchi K, Gao X, Panaccione R, Danese S, Dubinsky M, Schreiber S, Ilo D, Finney-Hayward T, Zhou W, Phillips C, Gonzalez YS, Shu L, Yao X, Zhou Q, Vermeire S. Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction Treatment. Clin Gastroenterol Hepatol. 2023 Aug;21(9):2347-2358.e6. doi: 10.1016/j.cgh.2022.11.029. Epub 2022 Dec 1. |
| 35644166 | Derived | Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hebuterne X, D'Haens G, Nakase H, Panes J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV Jr, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26. |
| FG002 | Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | Participants initially assigned to upadacitinib who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period. |
| FG003 | Part 2: Placebo / Upadacitinib 45 mg | Participants initially assigned to placebo who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period. |
| Received Treatment |
|
| COMPLETED |
|
| NOT COMPLETED |
|
|
| Part 2: Open-label Extension |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Upadacitinib 45 mg | Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. |
| BG001 | Placebo | Participants received placebo matching to upadacitinib once daily for 8 weeks. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Age, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| ||||||||||||||||
| Biologic-inadequate Responder (Bio-IR) Status | Biologic-inadequate responders (Bio-IR) are defined as participants who had inadequate response, loss of response, or intolerance to biologic therapy. Non-biologic-inadequate responders (non-bio-IR) are defined as participants who had inadequate response, loss of response, or intolerance to conventional therapy but had not failed biologic therapy. | Count of Participants | Participants |
| |||||||||||||||
| Baseline Corticosteroid Use | Count of Participants | Participants |
| ||||||||||||||||
| Adapted Mayo Score Strata | The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
The overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease. | Count of Participants | Participants |
| |||||||||||||||
| Bio-IR: Number of Prior Biologic Treatments | Biologic-inadequate responders | Count of Participants | Participants |
| |||||||||||||||
| Non-Bio-IR: Prior Exposure to Biologic Therapy | Non-biologic-inadequate responders | Count of Participants | Participants |
| |||||||||||||||
| Disease Duration | Mean | Standard Deviation | years |
| |||||||||||||||
| Adapted Mayo Score | The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
| Participants with available data | Mean | Standard Deviation | units on a scale |
| |||||||||||||
| Average Stool Frequency Subscore | Participants recorded stool frequency using an electronic subject diary on a daily basis. The stool frequency subscore (SFS) ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools more than normal Score 2: 3 to 4 stools more than normal Score 3: 5 or more stools more than normal | Participants with available data | Mean | Standard Deviation | units on a scale |
| |||||||||||||
| Average Rectal Bleeding Subscore | Participants recorded rectal bleeding in an electronic subject diary on a daily basis. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed | Participants with available data | Mean | Standard Deviation | units on a scale |
| |||||||||||||
| Average Endoscopy Subscore | Findings on endoscopy were scored according to the following: Score 0: Normal or inactive disease Score 1: Mild disease (erythema, decreased vascular pattern) Score 2: Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions) Score 3: Severe disease (spontaneous bleeding, ulceration) | Participants with available data | Mean | Standard Deviation | units on a scale |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 | The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
The overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as an Adapted Mayo score ≤ 2, with SFS ≤ 1 and not higher than Baseline, RBS of 0, and endoscopic subscore ≤ 1. | The Part 1 intent-to-treat population (ITT1) includes randomized participants who received at least 1 dose of study drug in Part 1. The ITT1 population excludes 6 participants from 1 site with non-compliance. Non-responder imputation incorporating multiple imputation to handle missing data due to Coronavirus Disease - 2019 (COVID-19) was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Endoscopic Improvement at Week 8 | Endoscopic improvement is defined as an endoscopic subscore of 0 or 1. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants With Endoscopic Remission at Week 8 | Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration). | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieved Clinical Response Per Adapted Mayo Score at Week 8 | The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:
The overall Adapted Mayo score ranges from 0 to 9 with higher scores representing more severe disease. Clinical response per the Adapted Mayo Score is defined as a decrease in Adapted Mayo score ≥ 2 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieved Clinical Response Per Partial Adapted Mayo Score at Week 2 | The Partial Adapted Mayo Score is a composite score of UC disease activity based on the following 2 subscores:
The overall Partial Adapted Mayo score ranges from 0 to 6 with higher scores representing more severe disease. Clinical response per Partial Adapted Mayo Score is defined as a decrease in Partial Adapted Mayo score ≥ 1 point and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 2 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage Of Participants Who Achieved Histologic-Endoscopic Mucosal Improvement at Week 8 | Histologic endoscopic mucosal improvement is defined as an endoscopic subscore of 0 or 1 and a Geboes score ≤ 3.1. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Reported No Bowel Urgency at Week 8 | Bowel urgency was assessed by participants in a subject diary completed once a day. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Reported No Abdominal Pain at Week 8 | Abdominal pain was assessed by participants in a subject diary completed once a day. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieved Histologic Improvement at Week 8 | Histologic improvement is defined as a decrease from Baseline in Geboes score. The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 90% Confidence Interval | percentage of participants | Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 8 | The Inflammatory Bowel Disease Questionnaire (IBDQ) is used to assess health-related quality of life (HRQoL) in patients with ulcerative colitis. It consists of 32 questions evaluating bowel and systemic symptoms, as well as emotional and social functions. Each question is answered on a scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224 with higher scores indicating better health-related quality of life. A positive change from Baseline indicates improvement. | ITT1 population with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases up to Week 8 was used except for measurements at or after the occurrence of UC-related corticosteroids intercurrent event were excluded. | Posted | Least Squares Mean | 95% Confidence Interval | units on a scale | Baseline (Week 0) to Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Percentage of Participants Who Achieved Mucosal Healing at Week 8 | Mucosal healing is defined as an endoscopic score of 0 and Geboes score < 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. | ITT1 population; non-responder imputation incorporating multiple imputation to handle missing data due to COVID-19 was used. | Posted | Number | 95% Confidence Interval | percentage of participants | Week 8 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Secondary | Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 8 | The FACIT fatigue questionnaire was developed to assess fatigue associated with anemia. It consists of 13 fatigue-related questions. Each question is answered on a 5-point Likert scale: 0 (not at all); 1 (a little bit); 2 (somewhat); 3 (quite a bit); and 4 (very much). The total score ranges from 0 to 52, where higher scores represent less fatigue, and a positive change from Baseline indicates improvement. | ITT1 population with available data; a mixed effect model repeat measurement (MMRM) analysis with data from observed cases up to Week 8 was used except for measurements at or after the occurrence of UC-related corticosteroids intercurrent event were excluded. | Posted | Least Squares Mean | 95% Confidence Interval | units on a scale | Baseline (Week 0) to Week 8 |
|
|
Part 1: From first dose of study drug up to 30 days after the last dose (up to 12 weeks) or until first dose of study drug in Part 2 or first dose of study drug in M14-234 (NCT02819635; maintenance study) or M14-533 (NCT03006068; long term extension). Part 2: From the first dose of study drug in Part 2 up to 30 days after last dose (up to 12 weeks) or until first dose of study drug in M14-234 (maintenance study) or the first dose date of study drug in M14-533 (long-term extension study).
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Part 1: Upadacitinib 45 mg | Participants received 45 mg upadacitinib once daily (QD) for 8 weeks. | 0 | 344 | 11 | 344 | 32 | 344 |
| EG001 | Part 1: Placebo | Participants received placebo matching to upadacitinib once daily for 8 weeks. | 0 | 177 | 8 | 177 | 11 | 177 |
| EG002 | Part 2: Upadacitinib 45 mg / Upadacitinib 45 mg | Participants initially assigned to upadacitinib who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1 received upadacitinib 45 mg once daily for 8 additional weeks in the open-label extension period. | 0 | 68 | 1 | 68 | 10 | 68 |
| EG003 | Part 2: Placebo / Upadacitinib 45 mg | Participants initially assigned to placebo who did not achieve clinical response per Adapted Mayo score at Week 8 in Part 1 received upadacitinib 45 mg once daily for 8 weeks in the open-label extension period. | 0 | 116 | 4 | 116 | 17 | 116 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANAEMIA | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| ABDOMINAL DISCOMFORT | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| ABDOMINAL PAIN LOWER | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| COLITIS | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| COLITIS ULCERATIVE | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| LARGE INTESTINE PERFORATION | Gastrointestinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| CHEST PAIN | General disorders | MedDRA 23.0 | Systematic Assessment |
| |
| COVID-19 PNEUMONIA | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| DENGUE FEVER | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| ENTEROCOCCAL INFECTION | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| ESCHERICHIA INFECTION | Infections and infestations | MedDRA 23.0 | Systematic Assessment |
| |
| GASTROINTESTINAL STOMA NECROSIS | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
| |
| HAND FRACTURE | Injury, poisoning and procedural complications | MedDRA 23.0 | Systematic Assessment |
| |
| MALNUTRITION | Metabolism and nutrition disorders | MedDRA 23.0 | Systematic Assessment |
| |
| ACUTE PSYCHOSIS | Psychiatric disorders | MedDRA 23.0 | Systematic Assessment |
| |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| PULMONARY EMBOLISM | Respiratory, thoracic and mediastinal disorders | MedDRA 23.0 | Systematic Assessment |
| |
| PYODERMA GANGRENOSUM | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
| |
| PELVIC VENOUS THROMBOSIS | Vascular disorders | MedDRA 23.0 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| ANAEMIA | Blood and lymphatic system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| PYREXIA | General disorders | MedDRA 23.0 | Systematic Assessment |
| |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | Investigations | MedDRA 23.0 | Systematic Assessment |
| |
| HEADACHE | Nervous system disorders | MedDRA 23.0 | Systematic Assessment |
| |
| ACNE | Skin and subcutaneous tissue disorders | MedDRA 23.0 | Systematic Assessment |
|
AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Global Medical Services | AbbVie | 800-633-9110 | abbvieclinicaltrials@abbvie.com |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Jan 19, 2021 | Oct 29, 2021 | SAP_001.pdf |
| ID | Term |
|---|---|
| D003093 | Colitis, Ulcerative |
| ID | Term |
|---|---|
| D003092 | Colitis |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D015212 | Inflammatory Bowel Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000613732 | upadacitinib |
Not provided
Not provided
Not provided
| Withdrawal by Subject |
|
| Other |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
|
|
| Participants |
|
|
|
| Units | Counts |
|---|
| Participants |
|
|
|
|
|
|
|
|
|
|
| Participants |
|
|
|
| Counts |
|---|
| Participants |
|
|
|
|
|
|